KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xylem (XYL) Research & Development (2016 - 2025)

Xylem has reported Research & Development over the past 16 years, most recently at $60.0 million for Q4 2025.

  • Quarterly results put Research & Development at $60.0 million for Q4 2025, up 3.45% from a year ago — trailing twelve months through Dec 2025 was $226.0 million (down 1.74% YoY), and the annual figure for FY2025 was $226.0 million, down 1.74%.
  • Research & Development for Q4 2025 was $60.0 million at Xylem, up from $52.0 million in the prior quarter.
  • Over the last five years, Research & Development for XYL hit a ceiling of $61.0 million in Q3 2023 and a floor of $47.0 million in Q3 2022.
  • Median Research & Development over the past 5 years was $54.5 million (2022), compared with a mean of $54.9 million.
  • Biggest five-year swings in Research & Development: increased 29.79% in 2023 and later decreased 9.84% in 2024.
  • Xylem's Research & Development stood at $52.0 million in 2021, then grew by 3.85% to $54.0 million in 2022, then increased by 11.11% to $60.0 million in 2023, then decreased by 3.33% to $58.0 million in 2024, then rose by 3.45% to $60.0 million in 2025.
  • The last three reported values for Research & Development were $60.0 million (Q4 2025), $52.0 million (Q3 2025), and $58.0 million (Q2 2025) per Business Quant data.